Gilead Sciences’ (GILD) “Outperform” Rating Reaffirmed at Cowen and Company
Gilead Sciences Inc. (NASDAQ:GILD)‘s stock had its “outperform” rating reiterated by research analysts at Cowen and Company in a research report issued to clients and investors on Monday. They presently have a $120.00 price target on the biopharmaceutical company’s stock. Cowen and Company’s price target suggests a potential upside of 65.20% from the company’s previous close.
Other research analysts also recently issued research reports about the stock. Piper Jaffray Cos. set a $108.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Sunday, August 21st. Jefferies Group reaffirmed a “hold” rating and issued a $97.00 price target on shares of Gilead Sciences in a report on Friday, July 15th. Argus downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $88.00 to $81.00 in a report on Friday, July 29th. RBC Capital Markets reaffirmed an “outperform” rating and issued a $105.00 price target (down previously from $120.00) on shares of Gilead Sciences in a report on Tuesday, July 26th. Finally, Barclays PLC reaffirmed an “overweight” rating on shares of Gilead Sciences in a report on Thursday, July 28th. Ten analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $103.60.
Gilead Sciences (NASDAQ:GILD) traded down 0.15% on Monday, hitting $72.64. The company’s stock had a trading volume of 8,171,260 shares. The firm has a 50 day moving average of $77.93 and a 200 day moving average of $84.45. The firm has a market cap of $95.86 billion, a price-to-earnings ratio of 6.38 and a beta of 1.10. Gilead Sciences has a 12 month low of $72.21 and a 12 month high of $111.11.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/gilead-sciences-gild-outperform-rating-reaffirmed-at-cowen-and-company.html
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.02 by $0.06. The firm earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.15 earnings per share. Equities research analysts forecast that Gilead Sciences will post $11.76 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Investors of record on Friday, September 16th were paid a dividend of $0.47 per share. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.59%. Gilead Sciences’s dividend payout ratio is presently 16.56%.
In related news, insider John C. Martin sold 100,000 shares of the company’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $80.50, for a total transaction of $8,050,000.00. Following the completion of the sale, the insider now owns 4,119,727 shares of the company’s stock, valued at approximately $331,638,023.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Paul Rutherford Carter sold 2,000 shares of the company’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $79.81, for a total transaction of $159,620.00. Following the sale, the executive vice president now directly owns 64,122 shares of the company’s stock, valued at approximately $5,117,576.82. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Van Hulzen Asset Management LLC boosted its stake in shares of Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares in the last quarter. Gemmer Asset Management LLC raised its position in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 175 shares during the last quarter. Joel Isaacson & Co. LLC raised its position in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the last quarter. Roble Belko & Company Inc raised its position in Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,035 shares during the last quarter. Finally, Pinkerton Retirement Specialists LLC raised its position in Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 1,582 shares during the last quarter. 78.00% of the stock is owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.